Reviewing ENDRA Life Sciences (NASDAQ:NDRA) & Sight Sciences (NASDAQ:SGHT)

Sight Sciences (NASDAQ:SGHT – Get Free Report) and ENDRA Life Sciences (NASDAQ:NDRA – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, dividends, valuation, institutional ownership and profitability.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Sight Sciences and ENDRA Life Sciences, as reported by MarketBeat.com.

Sight Sciences presently has a consensus price target of $7.75, suggesting a potential upside of 47.34%. ENDRA Life Sciences has a consensus price target of $25.00, suggesting a potential upside of 477.37%. Given ENDRA Life Sciences’ higher probable upside, analysts clearly believe ENDRA Life Sciences is more favorable than Sight Sciences.

Volatility and Risk

Sight Sciences has a beta of 2.38, indicating that its share price is 138% more volatile than the S&P 500. Comparatively, ENDRA Life Sciences has a beta of -0.06, indicating that its share price is 106% less volatile than the S&P 500.

Insider and Institutional Ownership

55.5% of Sight Sciences shares are held by institutional investors. Comparatively, 1.2% of ENDRA Life Sciences shares are held by institutional investors. 30.4% of Sight Sciences shares are held by insiders. Comparatively, 10.0% of ENDRA Life Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Sight Sciences and ENDRA Life Sciences’ net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Sight Sciences and ENDRA Life Sciences”s gross revenue, earnings per share and valuation.

ENDRA Life Sciences has lower revenue, but higher earnings than Sight Sciences. Sight Sciences is trading at a lower price-to-earnings ratio than ENDRA Life Sciences, indicating that it is currently the more affordable of the two stocks.

Summary

Sight Sciences beats ENDRA Life Sciences on 9 of the 13 factors compared between the two stocks.

About Sight Sciences

(Get Free Report)

Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. It also offers TearCare System, a wearable eyelid technology for adult patients with evaporative dry eye disease due to meibomian gland dysfunction, as well as related components. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. Sight Sciences, Inc. was incorporated in 2010 and is headquartered in Menlo Park, California.

About ENDRA Life Sciences

(Get Free Report)

ENDRA Life Sciences Inc. develops technologies to improve the capabilities of clinical diagnostic ultrasound. The company is developing thermo-acoustic enhanced ultrasound technology that uses radio frequency pulses to generate ultrasonic waves in tissue to create high-contrast images for use in the treatment of nonalcoholic fatty liver disease, as well as in tissue composition, temperature monitoring, vascular imaging, and tissue perfusion. It has a collaborative research agreement with General Electric Company. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.